key: cord-0968700-fc4sg70b authors: Valent, Peter; Akin, Cem; Bonadonna, Patrizia; Brockow, Knut; Niedoszytko, Marek; Nedoszytko, Boguslaw; Butterfield, Joseph H.; Alvarez-Twose, Ivan; Sotlar, Karl; Schwaab, Juliana; Jawhar, Mohamad; Reiter, Andreas; Castells, Mariana; Sperr, Wolfgang R.; Kluin-Nelemans, Hanneke C.; Hermine, Olivier; Gotlib, Jason; Zanotti, Roberta; Broesby-Olsen, Sigurd; Horny, Hans-Peter; Triggiani, Massimo; Siebenhaar, Frank; Orfao, Alberto; Metcalfe, Dean D.; Arock, Michel; Hartmann, Karin title: Risk and Management of Patients with Mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) Pandemic: Expert Opinions * date: 2020-06-17 journal: J Allergy Clin Immunol DOI: 10.1016/j.jaci.2020.06.009 sha: ae6a482d673b00ffbeeb7fba20a0bd8f966b559d doc_id: 968700 cord_uid: fc4sg70b Abstract The COVID-19 (SARS-CoV-2) pandemic has massively distorted our health care systems and caused catastrophic consequences in our affected communities. The number of victims continues to increase and patients at risk can only be protected to a degree, since the virulent state may be asymptomatic. Risk factors concerning COVID-19-induced morbidity and mortality include advanced age, an impaired immune system, cardiovascular or pulmonary diseases, obesity, diabetes mellitus, and cancer treated with chemotherapy. Here within, we discuss the risk and impact of COVID-19 in patients with mastocytosis and mast cell activation syndromes. As no published data are yet available, expert opinions are, by necessity, based on case experience and reports from patients. Whereas the overall risk to acquire the SARS-CoV-2 virus may not be elevated in mast cell disease, certain conditions may increase the risk of infected patients to develop severe COVID-19. These factors include certain co-morbidities, mast cell activation-related events affecting the cardiovascular or bronchopulmonary system and chemotherapy or immunosuppressive drugs. Therefore, such treatments should be carefully evaluated on a case-by-case basis during a COVID-19 infection. By contrast, other therapies, such as anti-mediator-type drugs, venom immunotherapy, or vitamin D, should be continued. Overall, patients with mast cell disorders should follow the general and local guidelines in the COVID-19 pandemic and advice from their medical provider. hospitalization, and up to 5% develop a life-threatening pneumonia. [13] [14] [15] [16] [17] [18] [19] The most 202 commonly reported symptoms are fever (>70%) and dry cough (>60%) ( Table 1) . [13] [14] [15] [16] [17] [18] [19] 203 Other typical symptoms are sore throat, anosmia and agneusia and a skin rash (Table 204 1). 13 neoplasms. 36 In acute leukemia or highly aggressive lymphomas, the dilemma is that 226 the underlying hematologic disease is by far a more dangerous enemy but is even more 227 critical when intensive treatment is started during a bacterial or viral pneumonia. immune cells and phagocytes. [37] [38] [39] [40] [41] [42] In viral diseases, MC may also serve as a viral 283 reservoir, as has been described for the human immunodeficiency virus. 43 The basic recommendation for patients with mastocytosis and MCAS is to adhere to 395 local and regional guidelines and recommendations in each country during the 396 COVID-19 pandemic and to avoid as much as possible any situation that might be 397 associated with an elevated risk of acquiring and/or distributing the infection. In addition, patients and doctors should avoid any situation that is associated with an 399 increased risk of a severe course of COVID-19 (Table 3) . This includes, among other 400 preventive measures, avoidance of immunosuppressive agents, heavily cytoreductive 401 treatments, or lymphocyte-depleting drugs (e.g., rituximab, alemtuzumab, or 402 cladribine) if such treatment can be postponed or can be avoided (Table 3) (Table 3) . Of note these drugs, with them in order to confirm the asymptomatic state and to relieve the patient´s fears. All patients with mastocytosis should continue their anti-mediator-type drugs, bis-435 phopshonates, and KIT-targeting kinase blocker (Table 3) . Other drugs should be 436 administered with caution and on the basis of COVID-19 severity, aggressiveness of 437 mastocytosis and the overall situation in each case (Table 3) Mast cells and mastocytosis Mast cells in allergy and infection: versatile effector and 489 regulatory cells in innate and adaptive immunity Mast cells, mastocytosis, and related disorders Diagnosis and classification of mast 495 cell proliferative disorders: delineation from immunologic diseases and non-mast cell 496 hematopoietic neoplasms Standards and standardization in mastocytosis: consensus statements on diagnostics, 500 treatment recommendations and response criteria Current treatment options in patients with 503 mastocytosis: status in 2015 and future perspectives The novel coronavirus originating in Wuhan, 531 China: challenges for global health governance Clinical features 534 of patients infected with 2019 novel coronavirus in Wuhan, China Clinical course and risk factors 538 for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective 539 cohort study Clinical characteristics of 542 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan Epidemiological and 546 clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, 547 China: a descriptive study Characteristics of and important lessons from the 550 COVID-19) outbreak in China: summary of a report of 551 72314 cases from the Chinese center for disease control and prevention Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized 604 Risk factors associated with 607 acute respiratory distress syndrome and death in patients with coronavirus disease 608 Risk factors associated with disease 611 progression in a cohort of patients infected with the 2019 novel coronavirus Cancer patients in SARS-615 CoV-2 infection: a nationwide analysis in China Coronaviruses and immunosuppressed patients. The facts during the 618 third epidemic Acute leukemia in the time of 621 COVID-19 Mast cell modulation of neutrophil 624 influx and bacterial clearance at sites of infection through TNF-alpha New and emerging roles for mast cells in host defence Recognition sites for microbes 631 and components of the immune system on human mast cells: relationship to CD 632 antigens and implications for host defense Human lung mast cells mediate pneumococcal cell death in response to activation by 637 pneumolysin Abraham 640 SN. Immune surveillance by mast cells during dengue infection promotes natural killer 641 (NK) and NKT-cell recruitment and viral clearance Mast cells are permissive for rhinovirus 645 replication: potential implications for asthma exacerbations Human tissue mast cells are an inducible reservoir of persistent HIV infection Mast cells 653 contribute to coronavirus-induced inflammation: new anti-inflammatory strategy Mendelian 657 inheritance of elevated serum tryptase associated with atopy and connective tissue 658 abnormalities Elevated basal serum 661 tryptase identifies a multisystem disorder associated with increased TPSAB1 copy 662 number First Identification 665 of an Inherited TPSAB1 Quintuplication in a Patient with Clonal Mast Cell Disease Evidence that Vitamin D Supplementation Could Reduce Risk of 670 Influenza and COVID-19 Infections and Deaths Optimisation of Vitamin D Status for Enhanced 673 Immuno-protection Against Covid-19 Early nutritional supplementation in non-critically ill patients hospitalized for the 2019 677 novel coronavirus disease (COVID-19): Rationale and feasibility of a shared 678 pragmatic protocol COVID-19 and vitamin D-Is there a link and an opportunity for 681 intervention? Considerations for obesity, vitamin D, and 684 physical activity amidst the COVID-19 pandemic *In patients with MCA, the symptoms are typically episodic and recurrent 729 and cannot be explained by other known disorders or conditions. In severe 730 cases a MCA syndrome (MCAS) may be diagnosed Most of the COVID-19-related symptoms are only recorded during the 732 Infection-period, and are transient; however, chronic pulmonary damage 733 with persistent dyspnea may be seen in rare, severe Score: ++, high specificity 735 -, not considered to be indicative of MCA or COVID-19 when Potential Risk Factors Predisposing for Severe COVID-19 Infection Reported in peer-reviewed journal with solid data (any evidence level) Abbreviations: NSAID: non-steroidal anti-inflammatory drugs ACE, angiotensin converting enzyme; ARB, angiotensin II type 1 receptor blocker Recommendations for Management of Distinct Forms of Mastocytosis during COVID-19 791 Category of mastocytosis Recommendations for management during the COVID-19 pandemic Non-advanced mastocytosis Cutaneous mastocytosis Continue to carry adrenaline autoinjector and emergency medications Continue H1 and H2 antihistamines Stop or reduce systemic glucocorticoids if possible If necessary, adjust systemic glucocorticoids to the phase of COVID-19** Continue vitamin D Postpone non-urgent medical visits for routine check-up Indolent systemic mastocytosis Continue to carry adrenaline autoinjector and emergency medications Continue H1 and H2 antihistamines Continue cromolyn sodium Stop or reduce systemic glucocorticoids if possible If necessary Continue midostaurin or other KIT-targeting tyrosine kinase inhibitors Stop or reduce systemic glucocorticoids if possible If necessary, adjust systemic glucocorticoids to the phase of COVID-19** Stop cladribine or other cytotoxic chemotherapy if possible Reduce or stop interferon-alpha if possible Reduce hydroxyurea doses, if possible, during active COVID-19 Continue midostaurin or other KIT-targeting tyrosine kinase inhibitors Stop or reduce systemic glucocorticoids if possible If necessary, adjust systemic glucocorticoids to the phase of COVID-19** Postpone cytotoxic chemotherapy, if possible, during active COVID-19 or switch to KIT-targeting drugs like midostaurin Reduce or stop interferon-alpha, if possible, during active COVID-19 Reduce hydroxyurea doses Continue H1 and H2 antihistamines Continue to carry adrenaline autoinjector and emergency medications Continue vitamin D Continue bisphosphonates and/or denosumab Mast cell leukemia Continue midostaurin or other KIT-targeting tyrosine kinase inhibitors Stop or reduce systemic glucocorticoids if possible If necessary, adjust systemic glucocorticoids to the phase of COVID-19** Postpone cytotoxic chemotherapy if possible Stop cladribine if possible Reduce or stop interferon-alpha, if possible, during active COVID-19 Reduce hydroxyurea during active COVID-19 Depending on the phase of COVID-19, systemic glucocorticoids are either avoided (earlier phases) 792 or even recommended (to block life-threatening lung inflammation)